BARCELONA, Spain, June 17, 2026
Skin Tech Pharma Group has announced that its flagship injectable treatment, RRS® HA LONG LASTING, has been honored with the prestigious Best Injectable in Skin Revitalization Award at the 2026 AMWC Aesthetic Medicine Awards, one of the most respected recognitions in the global aesthetic medicine industry. The award highlights the company’s growing leadership in the rapidly expanding Skin Builder category, recognizing the product’s contribution to advancing regenerative aesthetic medicine and meeting increasing demand for treatments that deliver natural-looking results while supporting long-term skin health. Since its commercial launch in 2021, RRS® HA LONG LASTING has achieved significant global adoption, with more than one million treatments performed worldwide, establishing a strong reputation for safety, efficacy, and patient satisfaction. The recognition further reinforces Skin Tech Pharma Group’s position as a leading innovator in aesthetic medicine and reflects the industry’s shift toward evidence-based solutions that combine aesthetic enhancement with skin quality improvement and healthy aging.
Award Recognizes Innovation in Skin Revitalization
The AMWC Aesthetic Medicine Awards celebrate groundbreaking innovations that shape the future of aesthetic and regenerative medicine. The selection of RRS® HA LONG LASTING as the leading injectable product in skin revitalization acknowledges its unique clinical approach and growing impact among healthcare professionals worldwide. Unlike conventional treatments that focus on a single aspect of skin rejuvenation, the product was designed to address multiple signs of aging simultaneously by improving hydration, elasticity, firmness, texture, and overall skin quality.
Industry experts have increasingly recognized the importance of regenerative approaches that support long-term skin health rather than delivering only temporary cosmetic improvements. The award reflects the product’s ability to meet evolving patient expectations for subtle, natural-looking outcomes while maintaining a strong safety profile and reproducible clinical results.
Dual-Action Skin Builder Redefines Aesthetic Treatment Standards
Advertisement
RRS® HA LONG LASTING is positioned as an advanced skin builder, a category that bridges the gap between traditional skin boosters and dermal fillers. The formulation combines cross-linked hyaluronic acid with a protective complex of 15 amino acids, creating a dual-action treatment designed to improve skin quality while supporting restoration of natural facial volume. This innovative approach enables patients to experience both immediate visible improvements and progressive enhancement of skin health over time. Clinical experience has demonstrated improvements in hydration, elasticity, skin texture, luminosity, fine lines, and wrinkles while maintaining natural facial expressions and appearance.
The product’s technology supports tissue regeneration and healthy aging, making it increasingly popular among practitioners seeking comprehensive solutions for age-related skin changes. Experts note that the treatment’s durability and safety profile distinguish it from many conventional aesthetic procedures currently available in the market.
Skin Tech Strengthens Global Leadership in Aesthetic Medicine
Founded in 1994, Skin Tech Pharma Group has built a global reputation for combining scientific research, pharmaceutical-quality manufacturing, and aesthetic innovation. The company operates advanced research and development facilities in Spain and continues to invest heavily in evidence-based technologies designed to improve patient outcomes. Over the past three decades, Skin Tech has introduced numerous innovations that have helped shape the modern aesthetic medicine sector. The latest recognition from AMWC further validates the company’s long-term strategy focused on scientific rigor, clinical performance, and sustainable innovation.
As demand for minimally invasive aesthetic procedures continues to grow worldwide, products such as RRS® HA LONG LASTING are expected to play an increasingly important role in the future of regenerative aesthetics. Industry observers believe the award will further strengthen the product’s international presence and reinforce Skin Tech Pharma Group’s status as a leading force in advancing aesthetic medicine technologies.
Source: Skin Tech Pharma Group press release
